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Apolipoprotein E (Apo E) is an important genetic risk factor for multiple neurological, vascular and cardiovascular diseases. Previously,
we reported Apo E isoprotein-specific modulation of tissue plasminogen activator (tPA) using an in vitro blood-clotting assay. Here, we
studied the conformational changes of Apo E2, E3 and E4 in the presence of tPA and vice versa using circular dichroism (CD) and dual
polarization interferometry (DPI). We report isoprotein and state-specific intermolecular interactions between the Apo E isoforms and tPA.
Apo E2 interaction with immobilized tPA leads to significant conformational changes which are not observed with Apo E3 or E4.
Additionally, tPA induces changes in helicity of lipidated Apo E2 whereas no detectible changes were observed in Apo E3 or E4. The
Tukey’s test for interaction indicated a significant (P < 0.001) interaction between tPA and Apo E2 in the lipidated environment. These results
may be important regarding the mechanism by which Apo E has isoprotein-specific effects on many biological processes and diseases
involving blood clotting, proteolysis and perfusion.
D 2004 Elsevier B.V. All rights reserved.Keywords: Apolipoprotein E; Tissue plasminogen activator; Thrombolysis; Protein–protein interaction; Mechanism; Dual polarization interferometry1. Introduction
Apolipoprotein E (Apo E), a member of a family of
lipid-associated proteins, has three common isoforms—E2,
E3, and E4, with E3 being the most common isoprotein
found in humans [1–3]. These monomeric isoforms com-
bine to form six Apo E phenotypes: E2/2, E2/3, E2/4 E3/3
E4/3 and E4/4 [4]. Apo E2, E3, and E4 each differ by
substitutions at residues 112 and 158 with amino acids cys
and arg. Isoform specific implications for several neuro-0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2004.04.004
Abbreviations: Apo E, apolipoprotein E; tPA, recombinant tissue
plasminogen activator; DPI, dual polarization interferometry; CD, circular
dichroism; ICH, intracerebral hemorrhage; TLC, thin layer chromatography
* Corresponding author. Tel.: +1-513-558-5480; fax: +1-513-558-
7009.
E-mail address: Susan.Biehle@uc.edu (S.J. Biehle).logical, vascular and cardiovascular diseases have been
reported [1–3,5]. This has raised questions as to the
function or biological activity of isoproteins of Apo E
[6–8].
Apo E has been linked to outcome and survival
following acute injury of the central nervous system as
well as the cardiovascular system [9–16]. The presence of
an E4 allele has been associated with a poor outcome
following severe head trauma or subarachnoid hemorrhage
(SAH) [11,12,15,17] and with reduced survival rates in
patients with an intracerebral hemorrhage (ICH) [9]. Others
have recently found that there is increased efficacy of
tissue plasminogen activator (tPA) in stroke patients that
have an Apo E2 phenotype, but no such benefit for an
Apo E2 phenotype was demonstrated in placebo-treated
patients, as measured either by clinical outcome or by CT-
lesion volume at 3 months post-stroke [4]. The putative
modification of tPA’s activity during acute ischemic stroke
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factor(s) of the clotting cascade. This change in tPA
activity might thus alter the brain’s response to reperfusion.
This may also provide an important clue for the apparent
increased activity of tPA therapy in stroke patients that
carry an Apo E2 allele.
Apo E has been found to interact with certain mole-
cules of the clotting cascade. Heparin has been shown to
bind to Apo E and decrease Apo E induced neurotoxicity
in culture [18–20]. Endothelial production of heparin
sulfate has been found to be stimulated by Apo E in
vitro [21]. Interestingly, heparin has been suggested to
enhance the lytic effect of tPA in stroke patients [22]. We
have previously reported that Apo E2 can increase, and
Apo E4 can decrease, tPA induced clot lysis in vitro [23].
In those studies, we presented thin layer chromatography
(TLC) data that suggested a direct interaction between the
tPA and the Apo E isoforms that were distinct between
E2, E3 and E4. The isoprotein-specific effects of Apo E
(especially that of Apo E2 versus E4) seem to support the
suggestion that Apo E isoproteins may have an effect on
the blood clot dynamics (formation/degradation) and that
this may be due to the direct interaction of Apo E with
certain factors in the blood.
Using circular dichroism (CD) and dual polarization
interferometry (DPI), the present study examines the
direct interactions between Apo E and tPA as a part of
the biochemical mechanism through which Apo E may
mediate its action on tPA-induced clot lysis. We report an
isoprotein-specific interaction of Apo E2 with tPA which
is distinct from a relative lack of specific interaction with
Apo E3 or E4 in the presence of model membranes, as
determined by the CD data. Those findings are corrobo-
rated by DPI where comparison with the tPA-E3 data
suggests that Apo E2 binds to tPA in a specific manner
forming a compacted quaternary structure of the two
molecules. Apo E4 binds to tPA in a specific fashion to
form a more open complex with tPA than E2. Both ofFig. 1. Schematic of dual polarization interferometer. Two simultaneous optical m
they travel along the glass slide (rather than perpendicular to it as in a microsc
immobilized protein. Any changes on the surface of the glass will result in two ind
size and density of the immobilized protein layer. (For color see online version).these interactions are distinct from the nonspecific nature
of the E3–tPA interaction.2. Materials and methods
2.1. Chemicals
All chemicals were reagent grade and obtained from
Fisher Scientific (Pittsburgh, PA) without further purifica-
tion unless otherwise noted. Recombinant tPA (Alteplase)
was reconstituted as suggested by the manufacturer, Gen-
entech (San Francisco, CA) and used without further puri-
fication. Apo E2, E3 and E4 were obtained and used without
further purification from PanVera (Madison, WI).
2.2. DPI
The measurement method employed utilizes two optical
waveguides stacked one on top of the other. The waveguides
confine light between defined boundaries (cf optical fibers).
This vertical structure is shown in Fig. 1. Polarized light
from a laser is fed to the end of the stack and therefore at the
moment of entry, the light waves in the top and bottom
waveguide must be in step (in ‘‘phase’’). Upon exposure of
the top surface of the upper (sensing) waveguide to a protein
that adheres to it, the speed of the light within it is changed.
The light in the lower waveguide experiences no such
influence and therefore progresses at a constant velocity
and provides an optical ‘reference’. Thus, when the light
exits from each of the waveguides, they are no longer in
phase. By simply allowing the output light to diverge from
the two waveguides and combine with each other at some
distance (in the ‘‘far-field’’), a series of light and dark bands
(interference fringes) is observed. The precise position of
the light and dark bands depends upon the phase relation-
ship of the light as it emerges from the two waveguides. As
further protein is added or removed from the sensor surface,easurements of the protein are made in orthogonal polarizations of light as
ope) and the nearfield associated with both polarizations interrogates the
ependent signals from the two polarizations which can be resolved into the
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changed and hence the position of the interference fringes
move. The phase changes are deduced from the distance of
fringe movement.
A second measurement is provided by introducing a
second polarization of light, at right angles to the first. This
responds differently to protein adsorption/desorption provid-
ing an independent second measurement. Using classical
optical theory, it is possible to interpret the two measure-
ments in terms of thickness and density for the adsorbed
protein. Using this technique, measurements in protein
thickness can be made to sub-atomic resolutions in real time
with full analysis of the technique published elsewhere [24].
It is important to recognize that this measurement embodies a
quantitative analytical technique rather than a simple ‘sen-
sor’ response function, providing absolute measurements
that can be related directly to the structure and function of
biomaterials immobilized to the measurement surface.
Analysis of molecular interactions between bound tPA
and Apo E was undertaken using an AnaLightR Bio200
(Farfield Sensors Ltd, Manchester, UK) dual polarization
interferometer. tPA (0.1 mg/ml) in phosphate buffered saline
(PBS), pH 7.4, was immobilized to a siloxynitride surface
functionalized with amine groups via the amine to amine
linker Bis (sulfosuccinimidyl) suberate, 2 mg/ml (BS3,
Pierce, Cheshire, UK). Following establishment of a stable
baseline with perfusion of PBS, Apo E isoforms (9.8 Ag/ml)
were perfused over the immobilized tPA for 3 min, then
incubated for 40 min before elution to stable signal. All
measurements were performed at 20 jC and captured at a
rate of 1 point/s.
2.3. CD
All CD measurements were made on a Jasco J715 at
room temperature. Typically, spectra were obtained fromFig. 2. Representative phase data for tPA immobilization and challenging with Apo
mass analysis of the immobilization of BS3 (42 min) tPA (50 m) and the subsequ250 to 180 nm with 0.1-nm step resolution at 50 nm/min.
The resultant spectra were the average of 4 scans using a
band width of 1.0 nm and a sensitivity of 20 mdeg. Each
spectrum had the solvent (vehicle) spectrum run separately
and subtracted out. For samples where tPA was titrated in,
the spectra of the same tPA titration into the vehicle were
recorded and subtracted from their respective Apo E spectra.
Thus, the resultant spectra are truly a representation of
changes in Apo E secondary structure, with no contribution
from the spectra of tPA or vehicle. Standard noise reduction
of the spectra was performed. Sodium dodecyl sulfate (SDS)
micelles were used in 100-fold excess (0.14 mM) of the Apo
E as a model membrane system since this more closely
simulates the in vivo conditions where Apo E is free to
exchange between the lipidated and non-lipidated states.
SDS micelles are often used as a model lipid membrane
system for structural and conformational studies of proteins
and peptides and do not denature proteins under these
conditions [25–27].
Typically, commercially available Apo E was diluted
further in the supplied media (0.7 M ammonium bicarbon-
ate) to the appropriate protein concentration (1.4 AM) for
spectra accumulation, either in the presence or absence of
SDS micelles. tPA was then titrated into the cuvette, with
spectra collection at each concentration. Concentrations of
tPA used were 0, 4.8, 7.1 and 11.7 Ag/ml. Changes in
ellipticity at 208 and 222 nm were recorded and plotted as a
function of tPA concentration as an indicator of changes in
secondary structure.
2.4. Statistical analysis
Statistical analysis using the Tukey’s single-degree of
freedom test for interaction [28] indicated that there is a very
significant interaction ( P < 0.001) between the tPA and the
isoprotein in a model lipid environment.E. Phase data for both polarizations, magnetic (Tm) and electronic (Te), and
ent interaction of Apo E2 (160 m). (For color see online version).
Fig. 4. Density of tPA layer in the presence of Apo E isoforms. The change
in density of the immobilized tPA layer upon addition of APO E isoforms,
with bars representing range of changes observed. As shown, the protein
layer density is increased considerably after the addition of Apo E2 whereas
density was decreased with addition of Apo E3 or E4.
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3.1. DPI
Fig. 2 shows a complete experiment in terms of phase
response for both polarizations and, additionally, mass is
displayed for a series of deposited layers upon the surface of
the sensor component. The tPA immobilization was repeat-
ed five times and the average thickness of the immobilized
tPA was 4.91F 0.55 nm with a surface loading of
2.87F 0.09 ng/mm2 and a density of 0.829F 0.096 g/
cm3. Mass and thickness changes occurring when the
immobilized tPA surface is challenged with Apo E2, E3
and Apo E4 are shown in Fig. 3. While the mass of bound
Apo E is similar regardless of the isoform used, the final
layer thickness observed is considerably greater in the case
of Apo E3 than in the case of Apo E2 or E4, indicative of
Apo E3 showing no specific affinity for tPA, in sharp
contrast to the complex formed between tPA and Apo E2.
Finally, the density changes which occur when Apo E
interacts with the immobilized tPA are shown in Fig. 4. It
can be seen that the layer is substantially denser after the
addition of Apo E2 while after the addition of Apo E3 or
E4, the layer is more diffuse.
3.2. CD
The CD spectrum of Apo E4 in an aqueous solution is
shown in Fig. 5 with increasing concentrations of tPA
titrated into the solution. Consistent with our previous
TLC results [23], in an aqueous (non-lipidated) solution,
Apo E4 has an interaction with tPA. Similar interactions
were observed when tPA was titrated into an aqueous
solutions of Apo E2 or E3 (data not shown). Correspond-
ingly, tPA was titrated into solutions of the Apo E isopro-
teins in the presence of SDS micelles (lipidated), in order to
more closely represent the in vivo conditions where Apo E
is free to partition between the free and lipidated states. As a
measure of secondary structural changes [29], in Fig. 6 we
plotted the ratio of ellipticity at 222/208 nm vs. tPA
concentration for each isoprotein. In this model of the inFig. 3. Mass/thickness of tPA layer in the presence of Apo E isoforms. Mass and th
Bars representing range of data observed, with the bar for E4 mass within the top b
protein layer is substantially greater for Apo E3 than either E2 or E4. (For colorvivo environment, Apo E3 and E4 do not appear to interact
with tPA, as observed by the lack of significant secondary
structural changes of the apolipoproteins. However, Apo E2
does appear to interact with tPA in a dose-dependent
fashion, under these—relatively physiological—conditions.
The significance of interaction was mainly due to the 11.7
Ag/ml tPA dose. However, even at the 7.1 Ag/ml tPA level,
the difference was significant (P < 0.05). As a control, each
of the isoforms was compared in the presence and absence
of SDS micelles, and no significant change in conformation
was detected (data not shown).4. Discussion
We found that Apo E2, E3 and E4 have distinct iso-
protein-specific interactions with tPA. Using two different
analytical techniques, we have confirmed our preliminary
TLC results [23]. A novel technique, DPI, was used to probe
the protein–protein interactions, and found support for
those data obtained using the more traditional CD. Below
we discuss the impact of these observations and the clinical
significance of the isoprotein-specific modulation of tPA
activity via Apo E. We make this argument because tPA isickness changes occurring when immobilized tPA is challenged with Apo E.
ar of the data. While the mass of Apo E bound is similar, the thickness of the
see online version).
Fig. 5. Representative CD spectra. Here we see the titration of tPA into 0.05 Ag/Al Apo E4 in 0.7 M ammonium bicarbonate (in the absence of SDS micelles).
tPA concentrations are 0, 0.005 and 0.012 Ag/Al for the thin blue, red dotted and thick blue traces, respectively. As can be seen, the typical alpha-helical region
of the protein spectra is dose-dependently altered, consistent with intermolecular interactions between the proteins. (For color see online version).
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conformational changes with the tPA. We infer from these
data that the isoprotein-specific interactions between tPA
and Apo E are the mechanism through which Apo E
modulates tPA’s proteolytic activity, resulting in altered
thrombolytic and proteolytic degradation.
4.1. Clot lysis
Clot lysis by administration of tPA to stroke patients
within 3 h following stroke onset is a beneficial therapy
approved by the FDA [22,30–33]. tPA therapy appears to
be enhanced with the Apo E2 phenotype [4]. In vitro
evidence indicates that Apo E4 is associated with a decreaseFig. 6. Molar ellipticity ratio as a function of tPA concentration. Ratio of
molar ellipticity at 222 to 208 nm as a function of tPA concentration for
Apolipoproteins E2, E3 and E4 in the presence of SDS micelles. An
indicator of 2j structure within the protein, this ratio suggests that tPA
interacts specifically with Apo E2, altering E2’s secondary structure under
these model membrane conditions. However, tPA does not appear to alter
the structure of Apo E3 or E4 under the same conditions, indicating that the
interactions are likely due to nonspecific, hydrophobic interactions,
consistent with the DPI results (Figs. 3 and 4), or that the interactions
simply do not elicit a conformational changes in the apolipoprotein. (For
color see online version).in the lytic action of tPA and that Apo E2 is associated with
an increase in lytic action [23]. It is likely that these results
are due to reduced or enhanced breakdown of fibrin caused
by Apo E modulation of tPA induced proteolysis, respec-
tively. tPA administration shifts this process (of clot forma-
tion and clot degradation) to favor clot degradation and Apo
E2 enhances the apparent activity of tPA, while Apo E4
inhibits the tPA induced proteolysis.
Specifically, in our previous study, tPA-induced clot
lysis (stimulated by exogenous tPA) was significantly
enhanced by supplementation with Apo E2 (EC50 of
0.20F 0.06 Ag/ml) as compared to tPA alone (0.72F
0.19). However, when Apo E4 was supplemented to the
clot lysis assay, there was a significant inhibition of clot
lysis (EC50 of 0.98F 0.23 Ag/ml) whereas there was no
significant change in tPA induced clot lysis caused by Apo
E3 [23]. Thus, the three isoproteins of Apo E had distinct
effects on thrombolysis in vitro. This phenomenon, while
interesting, did not determine whether there was a direct
and isoprotein-specific interaction between Apo E and tPA.
However, our findings could be explained by direct inter-
action of Apo E and tPA resulting in the isoprotein-specific
changes in tPA activity.
We also found that Apo E2 added to freshly obtained
blood, in the absence of exogenous tPA, reduced the overall
clot formation in vitro with no effect attributed to E3 or E4.
As tPA is an endogenous protease involved in the clotting
cascade, we believe our results are indicative of the exog-
enous Apo E2 enhancement of the endogenous tPA induced
clot lysis. Additionally, TLC experiments suggested an
interaction between Apo E2 and E4 with tPA in an aqueous
environment that was distinctly different than that of Apo
E3 with tPA [23]. In the current report, we found that the
isoproteins may have different propensities for interacting
with tPA in a lipid environment (Fig. 6). These results are
consistent with other work showing that the apolipoprotein
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and lipids [34,35].
In this study, we set out to determine the mechanism by
which Apo E isoproteins might have their effects on tPA
induced clot lysis. Within the body, there is a dynamic
partitioning of the apolipoproteins between the free and
lipidated state. This partitioning is also likely to be occur-
ring in the presence of the SDS micelles, thus making this
model of lipidated versus non-lipidated proteins well suited
for studying these protein–protein interactions. For these
studies, DPI and CD were used as appropriate and sensitive
analytical methods for probing the differences in the pro-
tein–protein interactions between tPA and Apo E.
4.2. DPI
DPI is an emerging analytical technique which is
capable of precise measurements of the thickness and
density of material attached to the surface of an optical
sensor chip. The technique has been used to measure
protein immobilization [24a], self-assembly of molecules
(such as surfactants [24b]) and ligand binding to proteins.
It has also been used to measure specific binding events
which typically involve an increase in density and decrease
in thickness (typically caused by conformational changes)
as binding takes place.
The data from the two polarizations in Fig. 2 are used to
calculate the thickness and density of material on the chip
surface. The data from the two polarizations are combined
to generate the data in Figs. 3 and 4. When the change in the
immobilized protein layer upon addition of the protein
isoforms is compared, it is clear that despite similar masses
of Apo E being bound to the tPA, the thickness and density
of the final layers are notably different. In the case of Apo
E2, the layer is considerably thinner and denser than is the
case for Apo E3 or E4. This suggests that the final structures
of the three are significantly different with tPA and that there
is a more intimate, and specific, interaction between tPA and
Apo E2 compared to the other two isoforms. The complex
formed between tPA and E4 is more diffuse than that of E2–
tPA, but the thickness and density values suggest a different
interaction from that of E3–tPA, with E4 binding to tPA in a
specific fashion to form a more open complex with tPA than
E2. These interactions are clearly distinct from the nonspe-
cific nature of the E3–tPA interaction.
4.3. CD
The use of CD for detecting conformational changes in
proteins has been well established [36,37]. The CD spec-
trum of proteins reflects the types and amounts of secondary
structure within the protein. For example, helical structures
have double minima at 208 and 222 nm, whereas h-sheet
structures elicit a single minimum at 216 nm. In contrast,
random coil conformations yield a minimum at 200 nm.
When these areas of secondary structure are altered, such aswhen a ligand binds, the CD spectrum is also altered. The
alterations in CD spectra can be used to determine which
specific regions of a structure undergo a conformational
change. In this way, the CD data can be used to map the
areas of interaction between two proteins. As has been
described and used by others [37,38], we used the ellipticity
ratio H222/H208 to measure the differences in interaction
between Apo E2, E3 and E4 with tPA.
From Fig. 5, we see that in an aqueous environment, Apo
E interacts with tPA, as judged by dose-dependent confor-
mational changes in the secondary structure of the protein.
This result is not surprising, however, as proteins in an
aqueous environment are likely to interact due to various
reasons, including nonspecific hydrophobic interactions
[39]. Fig. 6 plots the ratio of the ellipticity at 222:208 nm
vs. tPA concentration for each of the Apo E’s in a lipid
environment. This type of plot can be used as an indicator of
conformational changes, typical of intermolecular interac-
tions [37,38]. The implications for Fig. 6 can be one or a
combination of two things: that Apo E2 has a higher
propensity for interacting with tPA in a lipid environment
than E3 or E4, or that Apo E2 has a lower propensity for
incorporation into the SDS micelles, or some combination
of both. In either case, the isoproteins appear to interact
distinctly with tPA and in an isoprotein and state-dependent
manor.
4.4. Isoprotein effects of Apo E
There is a growing body of evidence that Apo E
isoproteins have numerous clinically relevant actions [40–
43]. There are many isoprotein-specific conditions, includ-
ing: cerebral amyloid angiopathy (CAA), Alzheimer’s dis-
ease (AD), heart disease, atherosclerosis, ICH and poor
outcome following head trauma and stroke. Arguably, all
of these conditions relate, in some way, to alterations in the
normal functioning of the clotting cascade and/or blood
flow. Taken together with our results, it appears as though
apolipoproteins E2 and E4 may play an active role in the
mechanism of disease and vascular dysfunction by altering
tPA induced proteolysis.
Many of the diseases found to be genetically or
correlatively linked to the Apo E isoproteins are generally
considered to be conditions of chronically compromised
blood flow and, hence, older age. It is possible, in the case
of Apo E4, that chronic inhibition or reduction of endog-
enous tPA potency may mediate the deposition of proteins
such as amyloid h-peptide, as in CAA and AD. Indeed, it
was recently found that the tPA-plasminogen cascade is
involved in the normal clearance of Ah [44]. It was therein
stated that ‘‘reduced activity of this system may contribute
to the progression of Alzheimer’s disease’’ [44]. Further,
reduced clot breakdown can lead to ICH via the resulting
increase in pressure in the microvasculature. Conversely, in
the case of Apo E2, where tPA potency is increased,
continual high rates of flow and protease activity can lead
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damage from shear stress, contributing to ICH and heart
disease.
The apparent interaction of Apo E with tPA can affect
clot degradation, and/or tPA’s proteolytic activity in several
ways. First, it could bind to the tPA, directly affecting its
clot degradation activity by increasing or decreasing its
ability to cleave plasminogen to plasmin. In the same way,
the activity of tPA has been shown previously to be altered
by binding to vascular smooth muscle cells with concom-
itant changes in conformation [46]. Alternatively, the clot
lysis activity could be altered by enhancing or inhibiting the
inactivation of tPA by plasminogen activator inhibitor 1
(PAI-1). This is important because PAI-1 is an established
modulator of tPA activity via direct and specific protein–
protein interactions [45]. Our isoprotein-specific interac-
tions of Apo E with tPA compliment the studies by
Aleshkrov et al. [45] who showed that fragments of PAI-1
had distinctly different binding capacities for tPA. To that
end, we have preliminary results (data not shown) indicating
that the effects on clot lysis of the Apo E’s are specific to
tPA. The activity of the closely related thrombolytic Ten-
ecteplase (Genentech), a derivative of tPA engineered spe-
cifically to be more stable to PAI-1 inhibition, does not
appear to be significantly affected by the presence of any of
the Apo E’s. These preliminary results, along with those
shown here, appear to indicate that Apo E mediates it effects
on clot lysis through isoprotein-specific, direct interactions
with tPA. More work is needed to determine the precise
mechanistic effects Apo E has on tPA’s conformation/kinetic
activity.5. Conclusions
From these studies, we conclude that Apo E interacts
directly with tPA in an isoprotein and state-specific manner,
potentially explaining the difference in their effects on tPA-
induced clot lysis. Explicitly, we found that Apo E2 has a
specific, intimate interaction with tPA in lipid and aqueous
solutions as judged by the CD and DPI data, whereas the
interaction of Apo E4 with tPA specific, but does not form a
compacted overall structure as E2 does. Furthermore, Apo
E3 does not appear to have a specific affinity for interacting
with tPA other than potentially through hydrophobic inter-
actions. The interactions of Apo E2 and E4 could directly
affect the ability of tPA (either endogenous or exogenous) to
cleave plasminogen to plasmin, therefore altering thrombol-
ysis and proteolysis dynamics.Acknowledgements
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